GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
C

Cisen Pharmaceutical Co 603367.SS · CNY

Health Care · Shanghai · 🇨🇳 China

Compare

13.12

-1.13%

Close of 9 Nov 2026, in CNY

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

About Cisen Pharmaceutical Co

Its shares trade on Shanghai under the ticker 603367.SS. It has been listed since 29 September 2017. In the fiscal year to 31 December 2025, it reported revenue of CN¥3.44bn and net income of CN¥421.2m. At that date it held total assets of CN¥7.60bn and shareholders' equity of CN¥6.19bn.

Cisen Pharmaceutical Ltd. engages in the manufacturing of comprehensive chemical and pharmaceutical products. The company is headquartered in Jining, Shandong. The company went IPO on 2017-09-29. The firm operates through two main segments. The Main Business segment is primarily involved in the manufacturing and sales of medicine, among which include infusion, freeze-dried powder, small volume injection, tablet, capsules, ointment, drops and active pharmaceutical ingredients, among others. The Other Business segment is mainly involved in the sales of raw materials and houses tenancy.

Figures and description from our data supplier, not checked against the company's own report.

Company facts

Sector
Health Care
Industry
Pharmaceuticals
Listed since
29 Sept 2017
Employees
3,413

Leadership

Pay as last reported

  • Mr. Zhenxin DuChairman of the Board, General Manager, since 2011
  • Mr. Xinbing XuChief Financial Officer, Secretary of the Board, Director, since 2024
  • Mr. Liushan HaoDeputy General Manager, Director, since 2011
  • Ms. Xiulian LuDeputy General Manager, Director, Chief Engineer, since 2011
  • Mr. Xiaoting CuiDeputy General Manager
  • Mr. Zelin RenDeputy General Manager
  • Mr. Xianglin ZhangDeputy General Manager
  • Mr. Tao GeDirector
  • Ms. Pengmei TianDirector
  • Mr. Wenchun CaiIndependent Director
  • Ms. Weijia WangIndependent Director
  • Mr. Ziran ZhangIndependent Director

Environmental, social and governance

Scores out of 100, from our data supplier

ESG
Overall
0
Environment
0
Social
0
Governance
0

SWOT analysis

AI-generated by our data supplier. Not written or checked by our editors.

AI-generated

Strengths

  • Headquartered in Jining, Shandong with 3,413 employees
  • Operates through two main segments: Main Business and Other Business
  • Manufactures and sells a variety of pharmaceutical products including infusions and tablets

Weaknesses

  • No specific weaknesses mentioned in the provided information
  • Limited detail on financial performance or market position
  • No information on competitive advantages or unique technologies

Opportunities

  • Growth potential in the pharmaceutical sector in China
  • Expansion of product lines within the Main Business segment
  • Potential for increased sales in raw materials and housing tenancy through the Other Business segment

Threats

  • Dependence on the Chinese pharmaceutical market
  • Competition from other pharmaceutical companies in the sector
  • Regulatory changes affecting pharmaceutical manufacturing

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.